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Microglia constitute the main immune defense in the central nervous system. In response
to neuronal injury, microglia become activated, acquire phagocytic properties, and release
a wide range of pro-inﬂammatory mediators that are essential for the annihilation of the
neuronal insult. Although the role of microglial activation in acute neuronal damage is well
deﬁned, the pathophysiological processes underlying destructive or protective role to neu-
rons following chronic exposure to microglial activation is still a subject of debate. It is likely
that chronic exposure induces detrimental effects by promoting neuronal death through the
release of neurotoxic factors. Positron emission tomography (PET) imaging with the use
of translocator protein (TSPO) radioligands provides an in vivo tool for tracking the progres-
sion and severity of neuroinﬂammation in neurodegenerative disease. TSPO expression
is correlated to the extent of microglial activation and the measurement of TSPO uptake
in vivo with PET is a useful indicator of active disease. Although understanding of the
interaction between radioligands andTSPO is not completely clear, there is a wide interest
in application of TSPO imaging in neurodegenerative disease. In this article, we aim to
review the applications of in vivo microglia imaging in neurodegenerative disorders such
as Parkinson’s disease, Huntington’s disease, Dementias, and Multiple Sclerosis.
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INTRODUCTION
Microglia account for approximately 10% of the adult brain cell
population and represent the ﬁrst and main form of immune
defense in the central nervous system (CNS; Lawson et al.,
1990; Kreutzberg, 1996). Upon CNS injury and disease, microglia
become activated and they can be identiﬁed and distinguished
from their resting phenotype based on a combination of mor-
phological and immunophenotypic changes (Dheen et al., 2007;
Ransohoff and Perry, 2009). Microglia initiate immune responses
by enhancing the expression of toll-like receptors (TLR) and a
wide range of pro-inﬂammatorymediators such as tumor necrosis
factor-alpha (TNFα), interleukin (IL)-1 and IL-6 for the removal
of the CNS threat (Suzumura et al., 1996; Hartlage-Rübsamen
et al., 1999; Bsibsi et al., 2002; Floden et al., 2005). Microglia
may also fulﬁll a neuroprotective role via the release of neu-
rotrophic factors and promotion of neurogenesis for the restora-
tion of normal physiology (Stadelmann et al., 2002). Hence, the
acute inﬂammatory response is generally beneﬁcial, as it tends
to minimize injury and promotes tissue repair. However, chronic
neuroinﬂammation is closely related to various neurodegenerative
disorders such as Parkinson’s disease (PD), Huntington’s disease
(HD), Dementias, and Multiple sclerosis (MS), although the con-
sequences of sustained microglial activation in these diseases is
unclear.
Activated microglia upregulate expression of the 18-kDa
translocator protein (TSPO; Chen and Guilarte, 2008; Cosenza-
Nashat et al., 2009; Scarf et al., 2009). TSPO are found in abun-
dance throughout the body in peripheral organs (i.e., liver and
adrenals), and hematogenous cells, but are present at very low lev-
els in the normal healthy CNS (Banati, 2002). Functionally, TSPO
has several biological functions including the control of choles-
terol transport and neurosteroid synthesis (Papadopoulos et al.,
2006), andmay also be involved in the release of pro-inﬂammatory
cytokines during inﬂammation (Choi et al., 2002; Wilms et al.,
2003).
Enhanced TSPO expression can be detected in vivo by using
positron emission tomography (PET) imaging with the selective
TSPO radioligand 11C-PK11195 (Benavides et al., 1988; Pike et al.,
1993; Banati et al., 1999), with evidence that increases in 11C-
PK11195 binding potential (BPND) correspond to activation of
microglia (Stephenson et al., 1995; Conway et al., 1998; Banati
et al., 2000). Although TSPO is also expressed by reactive astro-
cytes, a 11C-PK11195 PET study of patients with hippocampal
sclerosis, a condition histopathologically characterized by marked
astrogliosis, did not yield results that were signiﬁcantly different
to healthy normal controls (Banati et al., 1999). This is consistent
with the view that reactive astrocytes, in vivo, do not signiﬁcantly
contribute to the 11C-PK11195 signal. Therefore, in the absence
of invading blood borne cells or severe focal leakage of blood-
brain barrier, the increased PK11195 binding is likely to indicate
the transition of microglia from a resting to an activated state,
and is due to an increase in the number, rather than the afﬁnity,
of TSPO (Banati et al., 2000). Hence, the measurement of TSPO
uptake using PET provides an in vivo tool to monitor progres-
sion and severity of neuroinﬂammation and is a useful indicator
of active CNS disease. This article aims to review the use of PET
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imaging to promote the understanding of activated microglia in
neurodegenerative disease.
PARKINSON’S DISEASE AND RELATED DISORDERS
Parkinson’s disease is the second most common neurodegener-
ative disorder of the elderly and is associated with the motor
symptoms of tremor, bradykinesia, and rigidity. It is charac-
terized by the extended loss of dopaminergic neurons in the
substantia nigra pars compacta, resulting in a deﬁciency of
dopamine in the striatum (Braak et al., 2006), and the presence of
alpha-synuclein (α-synuclein)-containing lewy bodies. PD is the
most common of a group of parkinsonian movement disorders
that also includes Multiple system atrophy (MSA), Corticobasal
degeneration (CBD), and Progressive supranuclear palsy (PSP).
The presence of activated microglia close to dopaminergic neu-
rons in post-mortem PD patient brains (McGeer et al., 1988a;
Mogi et al., 1994; Langston et al., 1999; Imamura et al., 2003), and
PD animal models (Czlonkowska et al., 1996; Kim et al., 2009)
suggests a close relationship between neurodegeneration and neu-
roinﬂammation in PD. Numerous investigations have proposed a
deleterious role of microglial activation in PD based on the vul-
nerability of dopaminergic neurons to various microglia-derived
pro-inﬂammatory cytokines (Ferrari et al., 2006; Stone et al., 2009;
De Lella Ezcurra et al., 2010),whileα-synuclein can directly induce
activation of microglia (Zhang et al., 2005). However, it seems that
the plasticity of microglia must be considered with regards to their
contribution in PD, and their role; whether beneﬁcial or detrimen-
tal, it may depend on the stimuli present and the stage of disease
(Li et al., 2007; Michelucci et al., 2009; Sanchez-Guajardo et al.,
2010).
Further clues regarding the role of activated microglia has also
come from in vivo PET imaging studies (Table 1). Signiﬁcant
microglial activation, as reﬂected by an increase in 11C-PK11195
BPND was reported in the midbrain and putamen of PD patients
when compared to controls, and was found to correlate positively
with the motor severity of Parkinsonism (Ouchi et al., 2005; Bar-
tels et al., 2010). These ﬁndings suggest that activated microglia
has a pathogenic importance in the disease and indicate that the
early introductionof a neuroprotective drug to suppressmicroglial
activation could be favorable in PD. Additionally, PD patients
exhibited signiﬁcantly increased 11C-PK11195 BPND in the basal
ganglia, pons, and frontal and temporal cortical regions (Gerhard
et al., 2006a). In this study, the increased microglial activation
remained unchanged for 2 years, while the patients deteriorated
clinically during this period. Hence, it is likely that microglia are
activated early in PD, where they remain activated for longer peri-
ods and possibly drive progression of the disease (Gerhard et al.,
2006a).
Multiple system atrophy is a sporadic neurodegenerative dis-
order involving a progressive akinetic-rigid syndrome, autonomic
failure, and cerebellar dysfunction. It is associated by the appear-
ance of abnormal glial cytoplasmic inclusions (GCI) containing
(α-synuclein aggregates and neuronal loss within the nigrostri-
atal and olivopontocerebellar regions (Lantos and Papp, 1994).
The presence of activated microglia is also a prominent fea-
ture of MSA (Schwarz et al., 1998). In an in vivo PET study of
MSA patients, signiﬁcant 11C-PK11195 BPND was observed in
the putamen, pallidum, pons, substantia nigra pars compacta,
and dorsolateral prefrontal cortex, reﬂecting the known distri-
bution of neuropathological changes in MSA (Gerhard et al.,
2003). Although the role of microglia in MSA is inconclusive,
microglial activation localization correlated signiﬁcantly with the
locations of GCIs in speciﬁc neuroanatomical systems affected
in MSA (Ishizawa et al., 2004). A correlation between extent of
Table 1 | Positron emission tomography imaging studies assessing microglia in Parkinsonian disorders.
Study Disorder Subjects PET technique Main findings
Ouchi et al.
(2005)
PD 10 Early PD
patients, 10 NC
11C-PK11195 11C-PK11195 BPND in patients signiﬁcantly higher than controls
Midbrain 11C-PK11195 BPND values correlated positively with motor disability
Gerhard
et al. (2006a)
PD 18 PD patients,
11 NC
11C-PK11195 Signiﬁcantly increased 11C-PK11195 BPND in pons, basal ganglia, and frontal and
temporal cortical regions
11C-PK11195 signal remained stable for 2 years in subset of patients
Bartels et al.
(2010)
PD 14 PD patients,
8 NC
11C-PK11195 Higher contralateral putamen and midbrain 11C-PK11195 BPND in patients than controls
Gerhard
et al. (2003)
MSA 5 MSA
patients, 6 NC
11C-PK11195 MSA patients showed signiﬁcantly increased 11C-PK11195 BPND in regions reﬂecting
the known distribution of pathologic changes in MSA
Gerhard
et al. (2006b)
PSP 4 PSP patients,
7 NC
11C-PK11195 Signiﬁcantly increased 11C-PK11195 BPND in basal ganglia, midbrain, frontal lobe, and
cerebellum of patients compared to controls
Microglial activation remained stable as demonstrated in follow-up scans of two
patients
Gerhard
et al. (2004)
CBD 4 CBD
patients, 5 NC
11C-PK11195 CBD patients had signiﬁcantly increased 11C-PK11195 BPND in the cortical regions and
basal ganglia that correspond to known distribution of pathological changes in CBD
Henkel et al.
(2004)
CBD 1 CBD patient 11C-PK11195 Marked asymmetric microglial activation in corresponding areas of basal ganglia and
temporal and parietal cortices
BPND, binding potential; CBD, corticobasal degeneration; MSA, multiple system atrophy; NC, normal control; PD, Parkinson’s disease; PSP, progressive supranuclear
palsy.
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microglial activation and dopaminergic neurodegeneration has
also been reported (Stefanova et al., 2007).
Progressive supranuclear palsy is an adult-onset progressive
neurodegenerative disease of unknown cause, characterized by
PD-like symptoms such as postural instability and bradykinesia.
The pathological hallmark of the disease is neuroﬁbrillary tangles
consisting of hyperphosphorylated tau, accompanied by neuronal
loss in the thalamus, basal ganglia, and speciﬁc brainstem regions
(Hauw et al., 1994). Several early studies including immunohisto-
chemical investigations have conﬁrmed the possible involvement
of activatedmicroglia in PSP (Kida et al., 1992; Komori et al., 1998;
Ishizawa et al., 2000; Ishizawa and Dickson, 2001). 11C-PK11195
PET have also reported signiﬁcant levels of activated microglia in
brain regions known to be affected by the disease process such
as the midbrain, cerebellum, pons, frontal lobe, and basal gan-
glia (Gerhard et al., 2006b). Although these results were unable to
support a direct causal contribution to neurodegeneration in PSP,
they are at least suggestive of a role of microglia in the disease.
Corticobasal degeneration is a neurodegenerative disorder that
affects both cortical and basal ganglial regions, with considerable
clinical heterogeneity between patients. Typically, CBD features an
asymmetric hypokinetic-rigid syndrome, coupled with alien limb
phenomenon and cortical sensory impairment that is unrespon-
sive to dopaminergic therapy (Rebeiz et al., 1968;Gibb et al., 1989).
Information on the association of activated microglia in CBD is
limited, and mainly coming from immunohistochemical-based
assessments (Armstrong et al., 2000; Ishizawa and Dickson, 2001).
However, more recent in vivo PET investigations have attempted
to quantify microglial activation in CBD patients. Increased 11C-
PK11195 BPND was observed in regions such as the caudate
nucleus, putamen, substantia nigra pars compacta, pons, and
pre- and post central gyrus (Gerhard et al., 2004; Henkel et al.,
2004) that correspond to the expected neuropathological changes
seen in CBD (Ishizawa and Dickson, 2001; Dickson et al., 2002).
These results indicate an involvement of activated microglia in
pathogenesis of CBD.
HUNTINGTON’S DISEASE
Huntington’s disease is an autosomal, dominant inherited pro-
gressive neurodegenerative disorder associated with motor, cog-
nitive, and psychiatric symptoms. It is caused by an abnor-
mal polyglutamine-repeat expansion on the IT15 gene that
codes huntingtin, and involves the progressive loss of medium
spiny dopaminergic receptor-bearing striatal GABA-ergic neu-
rons (Vonsattel and DiFiglia, 1998). Although the role of chronic
neuroinﬂammation in the HD pathogenesis is not fully under-
stood, post-mortem assessments have reported high levels of
activated microglia close to degenerating neurons (McGeer et al.,
1988b; Messmer and Reynolds, 1998; Singhrao et al., 1999; Sapp
et al., 2001). Upregulated inﬂammatory cytokines have also been
detected in the striatum and plasma, indicative of an inﬂamma-
tory component in HD (Dalrymple et al., 2007; Björkqvist et al.,
2008).
In vivo imaging studies using 11C-PK11195 PET have found
increased microglial activation in both premanifest HD gene car-
riers and manifest HD patients when compared to healthy con-
trols (Table 2; Pavese et al., 2006; Tai et al., 2007; Politis et al.,
2008, 2011). In premanifest HD patients, signiﬁcant increases
in 11C-PK11195 BPND in the striatum and hypothalamus was
reported, which correlated inversely with neuronal dysfunction
as measured by 11C-Raclopride; a marker of dopaminergic D2/D3
receptor availability (Tai et al., 2007; Politis et al., 2008). Interest-
ingly, microglial activation in the striatum, and regions related to
cognitive function has been shown to predict the 5-year disease
clinical onset in premanifest HD patients (Tai et al., 2007; Politis
et al., 2011). These results imply that microglial activation is an
early event in the HD disease course, with a possible pathogenic
involvement that is associated with a subclinical progression of the
disease.
In manifest HD patients, signiﬁcant 11C-PK11195 BPND in the
striatum, hypothalamus, and various cortical regions was found,
that correlated with greater disease burden and higher motor dis-
ability (Pavese et al., 2006; Politis et al., 2008, 2011). The cortical
Table 2 | Positron emission tomography imaging studies assessing microglia in Huntington’s disease.
Study Subjects PET technique Main findings
Pavese et al. (2006) 11 manifest HD patients, 10
NC
11C-PK11195 Signiﬁcantly increased 11C-PK11195 BPND in patients than controls
Increased 11C-PK11195 uptake correlated positively with disease severity
Tai et al. (2007) 11 premanifest HD subjects,
10 NC
11C-PK11195 Signiﬁcantly higher striatal 11C-PK11195 BPND that correlated inversely with D2
receptor availability
Higher striatal uptake correlated with 5 year probability of clinical disease onset
Politis et al. (2008) 10 premanifest HD subjects,
9 manifest HD patients, 10
NC
11C-PK11195 Signiﬁcantly increased hypothalamic 11C-PK11195 BPND in both premanifest
and manifest subjects compared to controls
Inverse correlation between increased hypothalamic 11C-PK11195 BPND and
D2 receptor availability
Politis et al. (2011) 8 premanifest HD subjects,
8 manifest HD patients, 16
NC
11C-PK11195 In premanifest subjects, increased microglial activation in cognitive regions
correlated with 5 year probability of clinical disease onset.
In manifest HD patients, signiﬁcantly increased 11C-PK11195 BPND in globus
pallidus, anterior prefrontal cortex, and limbic striatum
BPND, binding potential; HD, Huntington’s disease; NC, normal control.
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microglial activation is likely to indicate the involvement of corti-
cal neurons in HD, a well-recognized phenomenon as the disease
progresses. Collectively, these ﬁndings are consistentwith the post-
mortem studies (Messmer and Reynolds, 1998; Sapp et al., 2001)
and suggest a detrimental microglial contribution to the ongoing
neuronal degeneration in HD.
DEMENTIA
Dementias are a group of disorders that are expected to affectmore
than 100 million people by 2050 raising remarkable ﬁnancial costs
for healthcare (Wimo et al., 2003). AD is the most common cause
of dementia and is the most common neurological disorder of the
elderly. AD is characterized by the presence of amyloid plaques,
neuroﬁbrillary tangles, and activated microglia (for review, see
Hardy and Selkoe, 2002). There is a plethora of evidence from
post-mortem human AD studies (McGeer et al., 1988a; Venneti
et al., 2009) and animal models (Frautschy et al., 1998; Stalder
et al., 1999; Leung et al., 2011) reporting a high accumulation of
activated microglia in close proximity with the amyloid plaques,
and upregulated levels of pro-inﬂammatory cytokines (Akiyama
et al., 2000; Eikelenboom et al., 2002).
Positron emission tomography enables a broad range of func-
tional processes to assess the AD brain in vivo (Table 3). 11C-
PK11195 has been used to demonstrate increased levels of acti-
vated microglia in both AD animal models (Venneti et al., 2009)
and AD patients (Cagnin et al., 2001; Edison et al., 2008; Yokokura
et al., 2011). In AD patients, signiﬁcant 11C-PK11195 BPND was
consistently observed in the temporal, parietal, and occipital cor-
tices, regions known to be affected by AD pathology (Cagnin
et al., 2001; Edison et al., 2008; Yokokura et al., 2011). The
increased activated microglia also inversely correlated with the
patient Mini-Mental State Examination (MMSE) scores, which is
compatible with a role of microglia in neuronal damage (Edison
et al., 2008). Interestingly, elevated levels of activated microglia
were also detected in patientswith amnesticmild cognitive impair-
ment (MCI; Okello et al., 2009a), although this was not observed
in another study assessing MCI patients (Wiley et al., 2009). MCI
could represent an early precursor stage of AD, since it was found
that MCI patients with increased amyloid load were signiﬁcantly
more likely to clinically convert to AD within 3 years (Okello et al.,
2009b). Therefore, microglial activation could be an early event in
the AD pathogenesis that begins at the MCI stage.
Despite the evidence suggestive of a pathogenic role of acti-
vated microglia in AD, it is hypothesized that the accumulation of
amyloid plaques is actually due to a failure in microglial clearance
mechanisms thatwouldnormally remove the protein (Bornemann
et al., 2001; DiCarlo et al., 2001; Napoli and Neumann, 2009). This
indicates a beneﬁcial, rather than detrimental role of microglia
in AD. Notwithstanding the abundance of activated microglia
close to senile plaques, they maybe inefﬁcient in the clearance of
amyloid, hence, resulting in aggregate formation (Bolmont et al.,
2008). It has been shown that in the presence of pro-inﬂammatory
cytokines, phagocytic functions of microglia are compromised
(Koenigsknecht-Talboo and Landreth, 2005). Therefore,microglia
may confer a dichotomous role in AD, where early microglial
activation is possibly neuroprotective involving the removal of
amyloid. However, chronic neuroinﬂammation may downregu-
late amyloid clearance mechanisms, thus, promoting aggregation
and progression of disease.
Frontotemporal lobar degeneration (FTLD) which includes
frontotemporal dementia is the name given to a groupof patholog-
ically, clinically, and genetically heterogeneous disorders involving
focal atrophy of the frontal and temporal lobes, while unlike
AD, with sparing of the parietal and occipital regions (Neary
et al., 1998). Another important dissimilarity between AD and
FTLD pathology is the absence of amyloid plaque formation
(Paulus et al., 1993; Mirra and Hyman, 2002). Rather, the
key histopathological features of FTLD, depending on subtype,
Table 3 | Positron emission tomography imaging studies assessing microglia in dementias.
Study Disorder Subjects PET technique Main findings
Cagnin et al.
(2001)
AD 8 AD patients, 15 NC 11C-PK11195 AD patients showed signiﬁcantly increased regional 11C-PK11195 BPND
in the entorhinal, temporoparietal, and cingulate cortex
Edison et al.
(2008)
AD 13 AD patients, 10 NC 11C-PK11195 Signiﬁcant increased 11C-PK11195 BPND in the cortical regions
Inverse correlation between increased cortical microglial activation and
MMSE scores
Yokokura
et al. (2011)
AD 11 AD patients, 10 NC 11C-PK11195 Signiﬁcantly increased 11C-PK11195 uptake in the parietotemporal
regions of patients than controls
Inverse correlation between dementia scores and 11C-PK11195 BPND
values
Wiley et al.
(2009)
AD, MCI 6 mild-moderate AD patients,
6 MCI patients, 5 NC
11C-PK11195 No signiﬁcant differences in brain 11C-PK11195 BPND between subject
groups
Okello et al.
(2009a)
MCI 14 MCI patients, 10 NC 11C-PK11195 5 of 13 MCI subjects had increased cortical 11C-PK11195 BPND
compared to controls
Cagnin et al.
(2004)
FTLD 5 FTLD patients, 8 NC 11C-PK11195 Signiﬁcantly increased 11C-PK11195 BPND in the frontotemporal regions
AD, Alzheimer’s disease; BPND, binding potential; FTLD, frontotemporal lobar degeneration; MCI, mild cognitive impairment; MMSE, mini-mental state examination;
NC, normal controls.
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includes tau deposition (including Pick bodies) and ubiquitin-
positive, tau-negative inclusions (Munoz et al., 2003; Uchihara
et al., 2003). In vivo PET imaging of FTLD patients detected
enhanced microglial activation in the expected frontotemporal
regions (Cagnin et al., 2004). In the same study, signiﬁcant 11C-
PK11195 BPND in the bilateral putamen is also consistent with
previous neuropathological data showing the involvement of the
basal ganglia in FTLD (Mirra and Hyman, 2002). These obser-
vations indicate the presence of an active microglial response that
reﬂects progressive neuronal degeneration. Importantly, the detec-
tion of increased microglial activation in affected regions in FTLD
suggests that microglial responses occur independently of amyloid
deposition, and that neuronal loss alone is enough to induce acti-
vation (Cagnin et al., 2004). However, whether this applies to AD
pathogenesis requires further investigation.
MULTIPLE SCLEROSIS
Multiple sclerosis is a disease characterized pathologically by
inﬂammatory demyelination and axonal transection, and is the
most common cause of non-traumatic disability in young adults
(Compston and Coles, 2008).
The involvement of activated microglia has long been pro-
posed in MS (Benveniste, 1997). Post-mortem investigations have
detected activated microglia in the cortical GM of MS patients
(De Groot et al., 2001; Peterson et al., 2001; Petzold et al., 2002),
while histopathological studies have implicated microglia in lesion
pathogenesis (for review, see Lassmann, 2008). An observed cor-
relation between neuronal loss and microglial activation was
reported in animal experimental MS (Rasmussen et al., 2007). Sig-
niﬁcant levels of activatedmicroglia was also found inMSpatients,
especially in the progressive forms of disease that are associated
with neurodegeneration (Kutzelnigg et al., 2005; Magliozzi et al.,
2010), and selective ablation of parenchymal microglia was able to
prevent demyelination and axonal damage (Heppner et al., 2005).
Pathological aspects of MS such as neuroinﬂammation,
demyelination, and neurodegeneration may be explored in vivo
with PET (for review, see Kiferle et al., 2011). PET with 11C-
PK11195 and other tracers has demonstrated inﬂammatory
processes with microglial involvement in MS (Figure 1; Table 4).
In animal experimental MS and human post-mortem brains it has
been shown that 11C-PK11195 uptake corresponds to the distrib-
ution pattern of activatedmicroglia (Banati et al., 2000). It has also
been demonstrated that there is increased 11C-PK11195 BPND in
areas of focal pathology identiﬁed by T1- and T2-weighted MRI
(Vowinckel et al., 1997; Banati et al., 2000) and in gadolinium-
enhanced T1-weighted MRI (Debruyne et al., 2003). Increased
11C-PK11195 BPND was observed in normal-appearing gray and
white anatomical structures (Banati et al., 2000; Debruyne et al.,
2003; Versijpt et al., 2005). This is in line with the hypothesis
that inﬂammatory processes initiated by microglia early in MS
may constitute the real burden of disease, associated with invisible
microglia-mediated damage that occur independently of relapses
(Kesselring, 1990; Confavreux et al., 2000). A positive correlation
has been suggested between ligand uptake and disease duration,
disability, and brain atrophy (Banati et al., 2000; Debruyne et al.,
2003;Versijpt et al., 2005), although the correlations were not con-
sistently replicated across the different studies. However, recent
FIGURE 1 | Positron emission tomography images showing increased
11C-PK11195 BPND in a Multiple Sclerosis patient (A) when compared to
a healthy normal control (B). Color bar represents intensity of 11C-PK11195
tracer binding (BPND). BPND, binding potential; MS, multiple sclerosis.
data from our group found a signiﬁcant association between
high 11C-PK11195 BPND in the cortical gray matter and disabil-
ity in patients with secondary progressive MS, and with higher
11C-PK11195 BPND in the secondary progressive group than the
relapse-remitting MS group (Politis et al., in press). These ﬁnd-
ings are consistent with a detrimental role of microglia in MS.
Enhanced microglial activation in MS has also been detected using
the more recently developed TSPO tracers 11C-vinpocetine and
11C-PBR28 (Vas et al., 2008; Oh et al., 2011).
Microglial activation may contribute to the mechanism of
axonal injury via the release of soluble factors that may either
directly or indirectly cause neuronal dysfunction (Peterson et al.,
2001; Barnett and Prineas, 2004;Dutta andTrapp, 2006; Zipp et al.,
2006; Dal Bianco et al., 2008; Lassmann, 2008; Magliozzi et al.,
2010), and consequently result in progressive increase in impair-
ment and disability. However, activated microglia may also exert
protective functions with MS through the release of neurotrophic
factors (Stadelmann et al., 2002; Napoli and Neumann, 2009), and
triggering of remyelination mechanisms (Li et al., 2005; Setzu et
al., 2006). This suggests a possible dichromatic role of microglia
in MS.
NEW TSPO LIGANDS
11C-PK11195 was the ﬁrst tracer to be consistently used for the
study of activatedmicroglia and neuroinﬂammation in vivo.How-
ever, limitations associated with the application of 11C-PK11195
include a high level of non-speciﬁc binding (Petit-Taboué et al.,
1991), and a poor signal to noise ratio,which complicates its quan-
tiﬁcation (Boutin et al., 2007). This has prompted the search for
novel PET tracers (termed, second generation radioligands) with
improved capacities to quantify TSPO expression.
Radioligands such as 11C-PBR28, 11C-DAA1106, 18F-
FEDAA1106, and 18F-PBR111 have recently been developed to
image TSPO in vivo (Gulyás et al., 2002; Ikoma et al., 2007; Fujita
et al., 2008; Vas et al., 2008; Yasuno et al., 2008; Oh et al., 2011;
for a review, see Chauveau et al., 2008). Published data using the
second generation ligands 11C-DAA1106 (Ikoma et al., 2007) and
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Table 4 | Positron emission tomography imaging studies assessing microglia in multiple sclerosis.
Study Subjects PET technique Main Findings
Vowinckel
et al. (1997)
2 MS patients 11C-PK11195 High 11C-PK11195 BPND in MRI-deﬁned active MS lesions
Banati et al.
(2000)
12 MS patients (RR, SP,
PP), 8 NC
11C-PK11195 Increased global and focal (in active MS lesions) 11C-PK11195 BPND in MS patients
Debruyne
et al. (2003)
22 MS patients (RR, SP,
PP), 7 NC
11C-PK11195 Increased 11C-PK11195 BPND in MRI-Gadolinium lesions. Higher uptake in T2 lesions
during relapse
Positive correlation between 11C-PK11195 BPND and disease duration
Versijpt et al.
(2005)
22 MS patients (RR, SP,
PP), 8 NC
11C-PK11195 Signiﬁcant correlation between brain atrophy and both disease duration and severity
For NAWM, 11C-PK11195 BPND increased with amount of atrophy
T2-lesional 11C-PK11195 BPND values decreased according to increasing atrophy
Vas et al.
(2008)
4 MS patients 11C-PK11195,
11C-vinpocetine
Regional uptake values increased in regions of brain damage for both tracers, but
markedly higher for 11C-vinpocetine than 11C-PK11195
Oh et al. (2011) 11 MS patients, 7 NC 11C-PBR28 High 11C-PBR28 in MRI-gadolinium lesions in patients
Increase in tracer uptake preceded appearance of gadolinium enhancement
No difference in global 11C-PBR28 uptake between patients and healthy controls
Politis et al. (in
press)
16 MS patients (RR,
SP), 8 NC
11C-PK11195 Signiﬁcant correlation between cortical GM 11C-PK11195 BPND and disease severity
Higher 11C-PK11195 in SP than RR patients
BPND, binding potential; GM, gray matter; MRI, magnetic resonance image; MS, multiple sclerosis; NAWM, normal-appearing white matter; NC, normal control; PP,
primary progressive multiple sclerosis; RR, relapse-remitting multiple sclerosis; SP, secondary progressive multiple sclerosis.
18F-FEDAA1106 (Fujimura et al., 2006) in humans were promis-
ing, with both tracers showing signiﬁcantly higher cerebral uptake
than 11C-PK11195. Furthermore, increased 11C-DAA1106 bind-
ing was reported in AD patients (Yasuno et al., 2008) that were
similar to the previous studies that used 11C-PK11195 (Cagnin
et al., 2001).
The only published study using the second generation radi-
oligand 11C-PBR28 found areas of focal increases in radiotracer
binding in the brain of MS patients (Oh et al., 2011). Interestingly,
the increased focal 11C-PBR28 binding preceded the development
of some gadolinium-enhancing lesions. Brain parenchymal 11C-
PBR28 binding in MS patients was positively correlated with the
duration of the disease, however it was not signiﬁcantly higher
than that of healthy volunteers. Interpretation of these results
is limited by the lack of characterization of the binding afﬁnity
pattern, which might have signiﬁcantly affected the comparison
between subjects.
It has been recently demonstrated that there are three dif-
ferent afﬁnity patterns for second generation TSPO ligands in
healthy volunteers as well as patients with MS, which was evident
with all the ligands tested (11C-PBR28; 11C-PBR06; 18F-PBR111;
Owen et al., 2010). This presents a methodological problem, as
differences in PET signal across subjects cannot be safely inter-
preted as differences in target density, but may reﬂect differences
in the afﬁnity pattern. A possible approach to solve this prob-
lem is based on the use of peripheral binding afﬁnity, which
can be characterized to classify subjects into one of the groups,
as differences in afﬁnity status between individuals have been
shown to be present on peripheral cells as well (Owen et al.,
2010).
Interestingly, the difference in binding patterns observed with
second generation radioligands was not observed with 11C-
PK11195. Also, in vitro autoradiography data using 11C-PK11195
suggest a receptor density (BMAX) signiﬁcantly higher than that
found using second generation ligands. It could be speculated that
11C-PK11195 and newer ligands bind to distinct sites within the
TSPO molecule.
Although,data obtained fromﬁrst generation studies have been
promising and suggested that 11C-PK11195 could be useful to
image acute inﬂammatory lesions and microglial activation in
MS, a conclusive demonstration of the potential of TSPO imaging
for the application as disease biomarker, indicative of microglial
activation in MS, is still lacking. Furthermore, despite second gen-
eration ligands constituting a potential improvement relative to
11C-PK11195 at least from a methodological point of view, a clear
advantage in their clinical application as disease biomarkers has
not been demonstrated yet.
For these reasons, we aim to characterize a second genera-
tion TSPO PET radioligand in vivo in humans, and to evaluate
its application as a disease biomarker in MS.
Among second generation TSPO tracers, 18F-PBR111 presents
different advantages, as there is low difference in its afﬁnity for
TSPO between high, medium, low afﬁnity binders. Also, it could
be potentially used in clinical applications as it is labeled with
ﬂuorine-18. Promising preclinical data, and ongoing studies in
neurological patients, suggest it could be a good choice amongst
second generation TSPO ligands to progress into studies in MS
patients.
CONCLUSION
Inﬂammation coupled with the presence of activated microglia
seems to be a common feature of a wide range of CNS diseases.
However, despite a large number of research studies, the exact
role of microglia in chronic neurodegenerative diseases remains
uncertain. In line with the high plasticity of microglia that allows
them to perform numerous CNS functions, microglia are likely to
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play a dichromatic role in disease, depending on signals present
in their microenvironment and the duration of activation. While
early microglial activation could represents a beneﬁcial response
(i.e., removal of CNS threat, promoting tissue repair and removal
of misfolded protein), chronic exposure could induces detrimental
effects by promoting neuronal death (i.e., through the sustained
release of neurotoxic factors), thus, contributing to progression
of disease. PET imaging with the use of TSPO radioligands pro-
vides a valuable tool that allows us to track the progression and
severity of neuroinﬂammation in the living brain, and is a use-
ful indicator of active CNS disease. Therefore, the early detection
of microglia using PET could offer opportunities for pharmaco-
logical interventions to limit the potential disruptive effects of
chronic microglial activation. Furthermore, with the development
of newer TSPO tracers, the potential for PET imaging research to
promote our understanding of activated microglia in CNS disease
can only increase.
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